{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:52:25Z","timestamp":1793674345202,"version":"4.5.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100002565","name":"Alzheimer\u2019s Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41591-026-04341-6","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:03:19Z","timestamp":1776243799000},"page":"2083-2095","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9422-8764","authenticated-orcid":false,"given":"Madison I. J.","family":"Honey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9713-116X","authenticated-orcid":false,"given":"Yanaika S.","family":"Hok-A-Hin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9723-5441","authenticated-orcid":false,"given":"Elisabeth H.","family":"Thijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-2766","authenticated-orcid":false,"given":"Katheryn A. Q.","family":"Cousins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babette","family":"van der Weijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisanne","family":"in \u2018t Veld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9989-4486","authenticated-orcid":false,"given":"Erik","family":"Stoops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sterre C. M.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora H.","family":"Duits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie F. H.","family":"de Houwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjado H. J.","family":"Morrema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-3245","authenticated-orcid":false,"given":"Daniel","family":"Alcolea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Ill\u00e1n-Gala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1340-638X","authenticated-orcid":false,"given":"Juan","family":"Fortea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2568-5478","authenticated-orcid":false,"given":"Alberto","family":"Lle\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-5064","authenticated-orcid":false,"given":"Adam L.","family":"Boxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-5098","authenticated-orcid":false,"given":"David J.","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4589-1180","authenticated-orcid":false,"given":"Edward B.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey T.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J. M.","family":"Hoozemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8766-6224","authenticated-orcid":false,"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"van der Ende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1989-7527","authenticated-orcid":false,"given":"Harro","family":"Seelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0341-7445","authenticated-orcid":false,"given":"Inge M. W.","family":"Verberk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4600-275X","authenticated-orcid":false,"given":"Li","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande","family":"Pijnenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4061-0837","authenticated-orcid":false,"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"4341_CR1","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini, M. L. et al. Classification of primary progressive aphasia and its variants. Neurology 76, 1006\u20131014 (2011).","journal-title":"Neurology"},{"key":"4341_CR2","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky, K. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456\u20132477 (2011).","journal-title":"Brain"},{"key":"4341_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrneurol.2012.117","volume":"8","author":"R Rademakers","year":"2012","unstructured":"Rademakers, R., Neumann, M. & Mackenzie, I. R. Advances in understanding the molecular basis of frontotemporal dementia. Nat. Rev. Neurol. 8, 423\u2013434 (2012).","journal-title":"Nat. Rev. Neurol."},{"key":"4341_CR4","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S0140-6736(15)00461-4","volume":"386","author":"J Bang","year":"2015","unstructured":"Bang, J., Spina, S. & Miller, B. L. Frontotemporal dementia. Lancet 386, 1672\u20131682 (2015).","journal-title":"Lancet"},{"key":"4341_CR5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/jnnp.2010.212225","volume":"82","author":"H Seelaar","year":"2011","unstructured":"Seelaar, H., Rohrer, J. D., Pijnenburg, Y. A., Fox, N. C. & van Swieten, J. C. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J. Neurol. Neurosurg. Psychiatry 82, 476\u2013486 (2011).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"4341_CR6","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00415-019-09363-4","volume":"266","author":"CV Greaves","year":"2019","unstructured":"Greaves, C. V. & Rohrer, J. D. An update on genetic frontotemporal dementia. J. Neurol. 266, 2075\u20132086 (2019).","journal-title":"J. Neurol."},{"key":"4341_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327497","volume":"93","author":"D Irwin","year":"2022","unstructured":"Irwin, D. Preparing for the age of therapeutic trials in frontotemporal lobar degeneration. J. Neurol. Neurosurg. Psychiatry 93, 115 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"4341_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jalz.2019.06.4956","volume":"16","author":"AL Boxer","year":"2020","unstructured":"Boxer, A. L. et al. New directions in clinical trials for frontotemporal lobar degeneration: methods and outcome measures. Alzheimers Dement. 16, 131\u2013143 (2020).","journal-title":"Alzheimers Dement."},{"key":"4341_CR9","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1136\/jnnp-2013-305972","volume":"85","author":"M Su\u00e1rez-Calvet","year":"2014","unstructured":"Su\u00e1rez-Calvet, M. et al. Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. J. Neurol. Neurosurg. Psychiatry 85, 684\u2013691 (2014).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"4341_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01091-8","volume":"14","author":"K Katisko","year":"2022","unstructured":"Katisko, K. et al. Serum total TDP-43 levels are decreased in frontotemporal dementia patients with C9orf72 repeat expansion or concomitant motoneuron disease phenotype. Alzheimers Res. Ther. 14, 151 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"4341_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.663637","volume":"12","author":"Y Ren","year":"2021","unstructured":"Ren, Y. et al. TDP-43 and phosphorylated TDP-43 levels in paired plasma and CSF samples in amyotrophic lateral sclerosis. Front. Neurol. 12, 663637 (2021).","journal-title":"Front. Neurol."},{"key":"4341_CR12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/jamaneurol.2013.6064","volume":"71","author":"M Grossman","year":"2014","unstructured":"Grossman, M. et al. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol. 71, 442\u2013448 (2014).","journal-title":"JAMA Neurol."},{"key":"4341_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ana.24996","volume":"82","author":"DJ Irwin","year":"2017","unstructured":"Irwin, D. J. et al. Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. Ann. Neurol. 82, 247\u2013258 (2017).","journal-title":"Ann. Neurol."},{"key":"4341_CR14","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1001\/jamaneurol.2018.0118","volume":"75","author":"A Lle\u00f3","year":"2018","unstructured":"Lle\u00f3, A. et al. A 2-step cerebrospinal algorithm for the selection of frontotemporal lobar degeneration subtypes. JAMA Neurol. 75, 738\u2013745 (2018).","journal-title":"JAMA Neurol."},{"key":"4341_CR15","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3233\/JAD-180409","volume":"66","author":"S Abu-Rumeileh","year":"2018","unstructured":"Abu-Rumeileh, S. et al. Cerebrospinal fluid biomarkers in patients with frontotemporal dementia spectrum: a single-center study. J. Alzheimers Dis. 66, 551\u2013563 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"4341_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/21678421.2014.971812","volume":"16","author":"B Borroni","year":"2015","unstructured":"Borroni, B. et al. CSF p-tau181\/tau ratio as biomarker for TDP pathology in frontotemporal dementia. Amyotroph. Lateral Scler. Frontotemporal Degener. 16, 86\u201391 (2015).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"4341_CR17","doi-asserted-by":"publisher","first-page":"e1231","DOI":"10.1212\/WNL.0000000000005261","volume":"90","author":"LHH Meeter","year":"2018","unstructured":"Meeter, L. H. H. et al. Clinical value of neurofilament and phospho-tau\/tau ratio in the frontotemporal dementia spectrum. Neurology 90, e1231\u2013e1239 (2018).","journal-title":"Neurology"},{"key":"4341_CR18","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1001\/jamaneurol.2022.3265","volume":"79","author":"KAQ Cousins","year":"2022","unstructured":"Cousins, K. A. Q. et al. Distinguishing frontotemporal lobar degeneration tau from TDP-43 using plasma biomarkers. JAMA Neurol. 79, 1155\u20131164 (2022).","journal-title":"JAMA Neurol."},{"key":"4341_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.dadm.2015.11.001","volume":"1","author":"YA Pijnenburg","year":"2015","unstructured":"Pijnenburg, Y. A., Verwey, N. A., van der Flier, W. M., Scheltens, P. & Teunissen, C. E. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau\/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement. (Amst.) 1, 505\u2013512 (2015).","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"4341_CR20","doi-asserted-by":"publisher","first-page":"7789","DOI":"10.1007\/s12035-018-0947-6","volume":"55","author":"E Feneberg","year":"2018","unstructured":"Feneberg, E., Gray, E., Ansorge, O., Talbot, K. & Turner, M. R. Towards a TDP-43-based biomarker for ALS and FTLD. Mol. Neurobiol. 55, 7789\u20137801 (2018).","journal-title":"Mol. Neurobiol."},{"key":"4341_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3233\/JAD-160386","volume":"55","author":"HB Kuiperij","year":"2017","unstructured":"Kuiperij, H. B. et al. Tau rather than TDP-43 proteins are potential cerebrospinal fluid biomarkers for frontotemporal lobar degeneration subtypes: a pilot study. J. Alzheimers Dis. 55, 585\u2013595 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"4341_CR22","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/s41591-024-02937-4","volume":"30","author":"M Chatterjee","year":"2024","unstructured":"Chatterjee, M. et al. Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS. Nat. Med. 30, 1771\u20131783 (2024).","journal-title":"Nat. Med."},{"key":"4341_CR23","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41591-023-02788-5","volume":"30","author":"KE Irwin","year":"2024","unstructured":"Irwin, K. E. et al. A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD. Nat. Med. 30, 382\u2013393 (2024).","journal-title":"Nat. Med."},{"key":"4341_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaa142","volume":"2","author":"C Scial\u00f2","year":"2020","unstructured":"Scial\u00f2, C. et al. TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients. Brain Commun. 2, fcaa142 (2020).","journal-title":"Brain Commun."},{"key":"4341_CR25","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/alz.13541","volume":"20","author":"E Fontana","year":"2024","unstructured":"Fontana, E. et al. Detection of TDP-43 seeding activity in the olfactory mucosa from patients with frontotemporal dementia. Alzheimers Dement. 20, 1156\u20131165 (2024).","journal-title":"Alzheimers Dement."},{"key":"4341_CR26","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1002\/alz.12643","volume":"18","author":"M Del Campo","year":"2022","unstructured":"Del Campo, M. et al. New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimers Dement. 18, 2292\u20132307 (2022).","journal-title":"Alzheimers Dement."},{"key":"4341_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1255","volume":"2","author":"TJ Cohen","year":"2011","unstructured":"Cohen, T. J. et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2, 252 (2011).","journal-title":"Nat. Commun."},{"key":"4341_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2016.03.005","volume":"90","author":"TE Tracy","year":"2016","unstructured":"Tracy, T. E. et al. Acetylated tau obstructs KIBRA-mediated signaling in synaptic plasticity and promotes tauopathy-related memory loss. Neuron 90, 245\u2013260 (2016).","journal-title":"Neuron"},{"key":"4341_CR29","first-page":"140","volume":"4","author":"B Lucke-Wold","year":"2017","unstructured":"Lucke-Wold, B. et al. Role of tau acetylation in Alzheimer\u2019s disease and chronic traumatic encephalopathy: the way forward for successful treatment. J. Neurol. Neurosurg. 4, 140 (2017).","journal-title":"J. Neurol. Neurosurg."},{"key":"4341_CR30","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.neuron.2010.08.044","volume":"67","author":"SW Min","year":"2010","unstructured":"Min, S. W. et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953\u2013966 (2010).","journal-title":"Neuron"},{"key":"4341_CR31","doi-asserted-by":"publisher","unstructured":"Zhang, S. et al. Acetylation of lysine 82 initiates TDP-43 nuclear loss of function by disrupting its nuclear import. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.09.04.611121 (2024).","DOI":"10.1101\/2024.09.04.611121"},{"key":"4341_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2024.168751","volume":"436","author":"YH Ko","year":"2024","unstructured":"Ko, Y. H. et al. Single acetylation-mimetic mutation in TDP-43 nuclear localization signal disrupts importin \u03b11\/\u03b2 signaling. J. Mol. Biol. 436, 168751 (2024).","journal-title":"J. Mol. Biol."},{"key":"4341_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6845","volume":"6","author":"TJ Cohen","year":"2015","unstructured":"Cohen, T. J. et al. An acetylation switch controls TDP-43 function and aggregation propensity. Nat. Commun. 6, 5845 (2015).","journal-title":"Nat. Commun."},{"key":"4341_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28822-7","volume":"13","author":"J Garcia Morato","year":"2022","unstructured":"Garcia Morato, J. et al. Sirtuin-1 sensitive lysine-136 acetylation drives phase separation and pathological aggregation of TDP-43. Nat. Commun. 13, 1223 (2022).","journal-title":"Nat. Commun."},{"key":"4341_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.202200410","volume":"23","author":"J Garc\u00eda Morato","year":"2023","unstructured":"Garc\u00eda Morato, J., Gloeckner, C. J. & Kahle, P. J. Proteomics elucidating physiological and pathological functions of TDP-43. Proteomics 23, e2200410 (2023).","journal-title":"Proteomics"},{"key":"4341_CR36","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/nm.3951","volume":"21","author":"SW Min","year":"2015","unstructured":"Min, S. W. et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat. Med. 21, 1154\u20131162 (2015).","journal-title":"Nat. Med."},{"key":"4341_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22501-9","volume":"12","author":"B Caballero","year":"2021","unstructured":"Caballero, B. et al. Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice. Nat. Commun. 12, 2238 (2021).","journal-title":"Nat. Commun."},{"key":"4341_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine, T. J. et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 123, 1\u201311 (2012).","journal-title":"Acta Neuropathol."},{"key":"4341_CR39","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1177\/13872877251352103","volume":"106","author":"E Liu","year":"2025","unstructured":"Liu, E. et al. Accuracy of blood-based neurofilament light to different genetic frontotemporal dementia from primary psychiatric disorders. J. Alzheimers Dis. 106, 1337\u20131354 (2025).","journal-title":"J. Alzheimers Dis."},{"key":"4341_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00882-5","volume":"20","author":"AHYS Hok","year":"2025","unstructured":"Hok, A. H. Y. S. et al. Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of frontotemporal dementia. Mol. Neurodegener. 20, 93 (2025).","journal-title":"Mol. Neurodegener."},{"key":"4341_CR41","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/jnen\/nlz141","volume":"79","author":"JL Robinson","year":"2020","unstructured":"Robinson, J. L. et al. Primary tau pathology, not copathology, correlates with clinical symptoms in PSP and CBD. J. Neuropathol. Exp. Neurol. 79, 296\u2013304 (2020).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"4341_CR42","doi-asserted-by":"publisher","first-page":"eaao6765","DOI":"10.1126\/scisignal.aao6765","volume":"11","author":"T Sen","year":"2018","unstructured":"Sen, T., Saha, P. & Sen, N. Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-\u03b2. Sci. Signal. 11, eaao6765 (2018).","journal-title":"Sci. Signal."},{"key":"4341_CR43","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00401-018-1948-2","volume":"137","author":"C Cicognola","year":"2019","unstructured":"Cicognola, C. et al. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer\u2019s disease. Acta Neuropathol. 137, 279\u2013296 (2019).","journal-title":"Acta Neuropathol."},{"key":"4341_CR44","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2174\/1567205016666190321161032","volume":"16","author":"YC Kim","year":"2019","unstructured":"Kim, Y. C. & Jeong, B. H. In silico evaluation of acetylation mimics in the 27 lysine residues of human tau protein. Curr. Alzheimer Res. 16, 379\u2013387 (2019).","journal-title":"Curr. Alzheimer Res."},{"key":"4341_CR45","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00401-013-1080-2","volume":"125","author":"LT Grinberg","year":"2013","unstructured":"Grinberg, L. T. et al. Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation. Acta Neuropathol. 125, 581\u2013593 (2013).","journal-title":"Acta Neuropathol."},{"key":"4341_CR46","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ajpath.2013.04.025","volume":"183","author":"DJ Irwin","year":"2013","unstructured":"Irwin, D. J. et al. Acetylated tau neuropathology in sporadic and hereditary tauopathies. Am. J. Pathol. 183, 344\u2013351 (2013).","journal-title":"Am. J. Pathol."},{"key":"4341_CR47","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/brain\/aws013","volume":"135","author":"DJ Irwin","year":"2012","unstructured":"Irwin, D. J. et al. Acetylated tau, a novel pathological signature in Alzheimer\u2019s disease and other tauopathies. Brain 135, 807\u2013818 (2012).","journal-title":"Brain"},{"key":"4341_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41672-1","volume":"14","author":"P Chakraborty","year":"2023","unstructured":"Chakraborty, P. et al. Acetylation discriminates disease-specific tau deposition. Nat. Commun. 14, 5919 (2023).","journal-title":"Nat. Commun."},{"key":"4341_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00653-0","volume":"18","author":"SO Tom\u00e9","year":"2023","unstructured":"Tom\u00e9, S. O. et al. TDP-43 pathology is associated with increased tau burdens and seeding. Mol. Neurodegener. 18, 71 (2023).","journal-title":"Mol. Neurodegener."},{"key":"4341_CR50","doi-asserted-by":"publisher","unstructured":"Rana, J. K. et al. CTE-type tau filaments in Alzheimer\u2019s disease with co-morbid LATE-NC. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.10.21.683735 (2025).","DOI":"10.1101\/2025.10.21.683735"},{"key":"4341_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0755-x","volume":"7","author":"KA Josephs","year":"2019","unstructured":"Josephs, K. A. et al. C-terminal and full length TDP-43 specie differ according to FTLD-TDP lesion type but not genetic mutation. Acta Neuropathol. Commun. 7, 100 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"4341_CR52","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/emboj.2009.324","volume":"29","author":"FC Fiesel","year":"2010","unstructured":"Fiesel, F. C. et al. Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. EMBO J. 29, 209\u2013221 (2010).","journal-title":"EMBO J."},{"key":"4341_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19317-4","volume":"11","author":"H Trzeciakiewicz","year":"2020","unstructured":"Trzeciakiewicz, H. et al. An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline. Nat. Commun. 11, 5522 (2020).","journal-title":"Nat. Commun."},{"key":"4341_CR54","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130\u2013133 (2006).","journal-title":"Science"},{"key":"4341_CR55","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3233\/JAD-132306","volume":"41","author":"WM Van der Flier","year":"2014","unstructured":"Van der Flier, W. M. et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J. Alzheimers Dis. 41, 313\u2013327 (2014).","journal-title":"J. Alzheimers Dis."},{"key":"4341_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0390-y","volume":"10","author":"RER Slot","year":"2018","unstructured":"Slot, R. E. R. et al. Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimers Res. Ther. 10, 76 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"4341_CR57","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.dadm.2018.08.006","volume":"10","author":"EAJ Willemse","year":"2018","unstructured":"Willemse, E. A. J. et al. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer\u2019s disease biomarkers in a nonacademic, multicenter memory clinic cohort: the ABIDE project. Alzheimers Dement. (Amst.) 10, 563\u2013572 (2018).","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"4341_CR58","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/21678421.2016.1267768","volume":"18","author":"MJ Strong","year":"2017","unstructured":"Strong, M. J. et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph. Lateral Scler. Frontotemporal Degener. 18, 153\u2013174 (2017).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"4341_CR59","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong, M. J. et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 80, 496\u2013503 (2013).","journal-title":"Neurology"},{"key":"4341_CR60","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov. Disord. 32, 853\u2013864 (2017).","journal-title":"Mov. Disord."},{"key":"4341_CR61","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 263\u2013269 (2011).","journal-title":"Alzheimers Dement."},{"key":"4341_CR62","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89, 88\u2013100 (2017).","journal-title":"Neurology"},{"key":"4341_CR63","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/joim.12190","volume":"275","author":"RC Petersen","year":"2014","unstructured":"Petersen, R. C. et al. Mild cognitive impairment: a concept in evolution. J. Intern. Med. 275, 214\u2013228 (2014).","journal-title":"J. Intern. Med."},{"key":"4341_CR64","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jagp.2013.02.002","volume":"22","author":"WA Krudop","year":"2014","unstructured":"Krudop, W. A. et al. Building a new paradigm for the early recognition of behavioral variant frontotemporal dementia: late onset frontal lobe syndrome study. Am. J. Geriatr. Psychiatry 22, 735\u2013740 (2014).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"4341_CR65","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5 5th edn (American Psychiatric Publishing, 2013).","DOI":"10.1176\/appi.books.9780890425596"},{"key":"4341_CR66","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1093\/brain\/awn234","volume":"131","author":"DS Knopman","year":"2008","unstructured":"Knopman, D. S. et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 131, 2957\u20132968 (2008).","journal-title":"Brain"},{"key":"4341_CR67","unstructured":"Verhage, F. Intelligentie en leeftijd: Onderzoek bij Nederlanders van twaalf tot zevenenzeventig jaar [in Dutch] (Van Gorcum, 1964)."},{"key":"4341_CR68","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ana.24885","volume":"81","author":"EG Spinelli","year":"2017","unstructured":"Spinelli, E. G. et al. Typical and atypical pathology in primary progressive aphasia variants. Ann. Neurol. 81, 430\u2013443 (2017).","journal-title":"Ann. Neurol."},{"key":"4341_CR69","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1097\/WAD.0b013e31815c3486","volume":"21","author":"IR Mackenzie","year":"2007","unstructured":"Mackenzie, I. R. The neuropathology of FTD associated with ALS. Alzheimer Dis. Assoc. Disord. 21, S44\u2013S49 (2007).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"4341_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2019.101644","volume":"180","author":"TW R\u00f6sler","year":"2019","unstructured":"R\u00f6sler, T. W. et al. Four-repeat tauopathies. Prog. Neurobiol. 180, 101644 (2019).","journal-title":"Prog. Neurobiol."},{"key":"4341_CR71","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1212\/WNL.0000000000000583","volume":"83","author":"EG Dopper","year":"2014","unstructured":"Dopper, E. G. et al. Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia. Neurology 83, e19\u2013e26 (2014).","journal-title":"Neurology"},{"key":"4341_CR72","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1212\/WNL.0000000000004393","volume":"89","author":"JM Papma","year":"2017","unstructured":"Papma, J. M. et al. Cognition and gray and white matter characteristics of presymptomatic C9orf72 repeat expansion. Neurology 89, 1256\u20131264 (2017).","journal-title":"Neurology"},{"key":"4341_CR73","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3109\/21678421.2015.1049183","volume":"16","author":"A Ludolph","year":"2015","unstructured":"Ludolph, A. et al. A revision of the El Escorial criteria\u20142015. Amyotroph. Lateral Scler. Frontotemporal Degener. 16, 291\u2013292 (2015).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"4341_CR74","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jalz.2013.06.003","volume":"10","author":"JB Toledo","year":"2014","unstructured":"Toledo, J. B. et al. A platform for discovery: the University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimers Dement. 10, 477\u2013484 (2014).","journal-title":"Alzheimers Dement."},{"key":"4341_CR75","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.trci.2019.09.005","volume":"5","author":"D Alcolea","year":"2019","unstructured":"Alcolea, D. et al. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: a data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimers Dement. (N.Y.) 5, 597\u2013609 (2019).","journal-title":"Alzheimers Dement. (N.Y.)"},{"key":"4341_CR76","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/acn3.50873","volume":"6","author":"D Alcolea","year":"2019","unstructured":"Alcolea, D. et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease on Lumipulse. Ann. Clin. Transl. Neurol. 6, 1815\u20131824 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"4341_CR77","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00702-014-1353-5","volume":"122","author":"NM Klioueva","year":"2015","unstructured":"Klioueva, N. M. et al. BrainNet Europe\u2019s code of conduct for brain banking. J. Neural Transm. (Vienna) 122, 937\u2013940 (2015).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"4341_CR78","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/jnc.13588","volume":"138","author":"IR Mackenzie","year":"2016","unstructured":"Mackenzie, I. R. & Neumann, M. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J. Neurochem. 138, 54\u201370 (2016).","journal-title":"J. Neurochem."},{"key":"4341_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman, B. T. et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 8, 1\u201313 (2012).","journal-title":"Alzheimers Dement."},{"key":"4341_CR80","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/NEN.0b013e31817d7a1d","volume":"67","author":"H Fujishiro","year":"2008","unstructured":"Fujishiro, H. et al. Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J. Neuropathol. Exp. Neurol. 67, 649\u2013656 (2008).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"4341_CR81","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3389\/fneur.2015.00179","volume":"6","author":"U Andreasson","year":"2015","unstructured":"Andreasson, U. et al. A practical guide to immunoassay method validation. Front. Neurol. 6, 179 (2015).","journal-title":"Front. Neurol."},{"key":"4341_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-024-00733-9","volume":"19","author":"C Parra Bravo","year":"2024","unstructured":"Parra Bravo, C. et al. Anti-acetylated-tau immunotherapy is neuroprotective in tauopathy and brain injury. Mol. Neurodegener. 19, 51 (2024).","journal-title":"Mol. Neurodegener."},{"key":"4341_CR83","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","volume":"73","author":"CE Teunissen","year":"2009","unstructured":"Teunissen, C. E. et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73, 1914\u20131922 (2009).","journal-title":"Neurology"},{"key":"4341_CR84","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1002\/acn3.51676","volume":"9","author":"L Vermunt","year":"2022","unstructured":"Vermunt, L. et al. Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface. Ann. Clin. Transl. Neurol. 9, 1832\u20131837 (2022).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"4341_CR85","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13195-025-01700-2","volume":"17","author":"JIR Dijkstra","year":"2025","unstructured":"Dijkstra, J. I. R. et al. TREM2 risk variants and associated endophenotypes in Alzheimer\u2019s disease. Alzheimers Res. Ther. 17, 57 (2025).","journal-title":"Alzheimers Res. Ther."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04341-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04341-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04341-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:03:10Z","timestamp":1781791390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04341-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":85,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4341"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04341-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.I.J.H is listed as an inventor on a patent application concerning the use of AcTau174 as a biomarker (EPO application EP26151547.2). L.G. is the founder and consultant of Aeton Therapeutics and is listed as an inventor on a patent application concerning the AcTau antibody used in this study. J.J.M.H. is currently employed by F. Hoffmann-La Roche AG. H.S. is a member of the European Reference Network for Rare Neurological Diseases\u2014Project ID 739510. I.M.W.V. receives speaker honorarium from Quanterix and is a consultant to Neurogen Biomarking. I.M.W.V. also participates in a collaborative research project with Quanterix and Olink, supported by PPP allowance from Health~Holland, and additional collaborative projects with Nitrase Therapeutics, Roche Diagnostics and Sysmex. All payments are made directly to her institution. E.H.T. is a cofounder and Chief Scientific Officer of Neurogen Biomarking. She is listed as an inventor on a patent application concerning the use of AcTau174 as a biomarker (EPO application EP26151547.2). D.J.I. reports NIH grants and industry funding to his institution for clinical trials by Alector, CervoMed, Denali, Passage Bio and Prevail. Funding sources are P01-\n                      \n                      and P30-AG-072979. E.B.L. has received consulting fees from Eli Lilly. D.A. has participated in advisory boards for Fujirebio-Europe, Roche Diagnostics, Grifols S.A. and Lilly, and has received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmac\u00e9utica S.L., Zambon S.A.U., Neuraxpharm, Alter Medica, Lilly and Esteve Pharmaceuticals S.A. D.A. also holds a patent for markers of synaptopathy in neurodegenerative diseases (licensed to ADx NeuroSciences N.V., WO2019175379). J.F. reported receiving personal fees for service on the advisory boards, adjudication committees or speaker honoraria from Alnylam, AC Immune, Adamed, Alzheon, Biogen, Eisai, Esteve, Fujirebio, Ionis, Laboratorios Carnot, Life Molecular Imaging, Lilly, Novo Nordisk, Perha, Roche, Zambon and outside the submitted work. He reports holding a patent for markers of synaptopathy in neurodegenerative disease (licensed to ADx, EPI8382175.0). A.L. participated in advisory board meetings from Almirall, Beckman-Coulter, Biogen, Eisai, Fujirebio-Europe, Grifols, Lilly, Novartis, Novo Nordisk, Nutricia, Otsuka Pharmaceutical, Roche and Zambon, and received speaker honoraria from Almirall, Esteve, Lilly, Biogen, KRKA, Nutricia and Zambon. A.L. is co-author of a patent on antibodies for amyloid precursor, methods and uses thereof European priority (EP25382226). I.I.-G. participated in advisory boards from UCB and Nutricia, and received speaker honoraria from Almirall, Esteve Pharmaceuticals S.A., Kern Pharma, Krka Farmac\u00e9utica S.L., Lilly, Nutricia and Zambon S.A.U. A.L.B. served as a paid consultant to Alector, Alexion, Arrowhead, Arvinas, Eli Lilly, Janssen, Merck, Neurocrine, Novartis, Oligomerix, Ono, Oscotec, Switch and Transposon. He is a scientific cofounder of Neurovanda. His institution received research support from Biogen and Eisai for serving as a site investigator for clinical trials, as well as from Regeneron. E.S. is an employee of ADx NeuroSciences, Gent, Belgium, which is a partner in ABOARD (\n                      \n                      ). As of 1 November, 2025, W.M.v.d.F. is executive director at Alzheimer Nederland, Amersfoort, the Netherlands. Before 1 November 2025, research programs of W.M.v.d.F. have been supported by ZonMW, NWO, EU JPND, EU-IHI, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Noaber foundation, Pieter Houbolt Fonds, Gieskes-Strijbis Fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, Philips, Biogen MA, Novartis-NL, Life-MI, AVID, Roche BV, Eli Lilly-NL, Fujifilm, Eisai, Combinostics. W.M.v.d.F. is a recipient of ABOARD, which is a public\u2013private partnership receiving funding from ZonMW (73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP allowance; LSHM20106). Before 1 November 2025, W.M.v.d.F. served as an invited speaker for Biogen MA, Danone, Eisai, WebMD Neurology (Medscape), Novo Nordisk, Springer Healthcare and European Brain Council. W.M.v.d.F has been a consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA, Eisai, Eli Lilly, Owkin France and Nationale Nederlanden Ventures. W.M.v.d.F has participated in advisory boards of Biogen MA, Roche and Eli Lilly. In 2024\u20132025, W.M.v.d.F has been a member of the steering committee of phase 3 EVOKE\/EVOKE+ studies (Novo Nordisk). In 2025, W.M.v.d.F has been a member of the steering committee op phase 3 Trontinemab study (Roche). All funding has been paid to Amsterdam UMC. W.M.v.d.F was associate editor of Alzheimer\u2019s Research & Therapy in 2020\/2021. W.M.v.d.F was associate editor at Brain 2021\u20132025. W.M.v.d.F is chair of the Scientific Leadership Group of InRAD. W.M.v.d.F is also a member of the supervisory board (Raad van Toezicht) Trimbos Instituut. C.E.T. is listed as an inventor on a patent application concerning the use of AcTau174 as a biomarker (EPO application EP26151547.2). C.E.T. has \u2018research contracts\u2019 with Acumen, ADx Neurosciences, AC Immune, Alamar, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, C2N diagnostics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Instant Nano Biosensors, Merck, Muna, Nitrase Therapeutics, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Sysmex, Toyama, Vaccinex, Vivoryon. She is editor-in-chief of Alzheimer Research and Therapy, and serves on editorial boards of Molecular Neurodegeneration, Alzheimer\u2019s & Dementia, Neurology\u2014Neuroimmunology & Neuroinflammation, Medidact Neurologie\/Springer, and is a committee member to define guidelines for Cognitive disturbances, and one for acute Neurology in the Netherlands. She has \u2018consultancy\/speaker contracts\u2019 for Aribio, Biogen, Beckman-Coulter, Cognition Therapeutics, Danaher, Eisai, Eli Lilly, Janssen, Merck, Neurogen Biomarking, Nordic Biosciences, Novo Nordisk, Novartis, Olink, Quanterix, Roche, Sanofi and Veravas. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}